News stories about Prana Biotechnology (NASDAQ:PRAN) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Prana Biotechnology earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.6452426300957 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of Prana Biotechnology (NASDAQ PRAN) opened at 2.50 on Friday. Prana Biotechnology has a one year low of $1.52 and a one year high of $5.46. The company’s market capitalization is $3.71 million. The firm has a 50-day moving average of $2.69 and a 200-day moving average of $2.50.

TRADEMARK VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/08/27/prana-biotechnology-pran-receives-daily-media-sentiment-score-of-0-12.html.

Prana Biotechnology Company Profile

Prana Biotechnology Limited is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer’s disease, Huntington disease, Parkinson’s disease and other neurological disorders.

Insider Buying and Selling by Quarter for Prana Biotechnology (NASDAQ:PRAN)

Receive News & Stock Ratings for Prana Biotechnology Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prana Biotechnology Ltd and related stocks with our FREE daily email newsletter.